OverviewSuggest Edit

Opiant Pharmaceuticals is a specialty pharmaceutical company developing pharmacological treatments for substance use, addictive and eating disorders. The Company has developed NARCAN (naloxone hydrochloride) Nasal Spray, a treatment to reverse opioid overdoses, which was conceived, licensed, developed and approved by the United States Food and Drug Administration (FDA). The Company's pipeline of product candidates includes a treatment for Binge Eating Disorder (BED), a treatment for Bulimia Nervosa (BN), a treatment for Cocaine Use Disorder (CocUD) and a heroin vaccine. Opiant Pharmaceuticals is also focused on other treatment opportunities.

TypePublic
Founded2009
HQSanta Monica, US
Websiteopiant.com

Latest Updates

Employees (est.) (Mar 2019)16(+15%)
Revenue (FY, 2018)$14 M(-24%)
Share Price (Oct 2019)$14.2 (+2%)

Key People/Management at Opiant Pharmaceuticals

Roger Crystal

Roger Crystal

CEO
Kevin Pollack

Kevin Pollack

CFO
Phil Skolnick

Phil Skolnick

Chief Scientific Officer
Arvind Agrawal

Arvind Agrawal

Executive Vice President, Medical Affairs
Mark Ellison

Mark Ellison

Executive Vice President Development, Manufacturing and Quality
Quan Vu

Quan Vu

Vice President, Corporate Development
Show more

Opiant Pharmaceuticals Office Locations

Opiant Pharmaceuticals has an office in Santa Monica
Santa Monica, US (HQ)
401 Wilshire Blvd 12th Floor
Show all (1)

Opiant Pharmaceuticals Financials and Metrics

Opiant Pharmaceuticals Revenue

Opiant Pharmaceuticals's revenue was reported to be $13.98 m in FY, 2018 which is a 24.2% decrease from the previous period.
USD

Revenue (Q2, 2019)

6.8m

Net income (Q2, 2019)

1.6m

EBIT (Q2, 2019)

1.4m

Market capitalization (11-Oct-2019)

57.4m

Closing stock price (11-Oct-2019)

14.2

Cash (30-Jun-2019)

23.9m
Opiant Pharmaceuticals's current market capitalization is $57.4 m.
Annual
USDFY, 2017FY, 2018

Revenue

18.4m14.0m

Revenue growth, %

(24%)

Sales and marketing expense

1.7m213.9k

General and administrative expense

6.5m11.3m
Quarterly
USDQ2, 2017Q3, 2017Q1, 2018Q1, 2018Q2, 2018Q3, 2018Q1, 2019Q2, 2019

Revenue

13.5m18.1k22.0k1.7m3.2m4.4m5.4m6.8m

Sales and marketing expense

1.2m84.4k

General and administrative expense

1.4m2.0m4.0m3.0m2.9m3.4m3.7m3.7m

R&D expense

344.8k1.1m1.6m2.4m1.6m1.9m3.6m1.6m
Annual
USDFY, 2014FY, 2015FY, 2016FY, 2017FY, 2018

Cash

254.8k434.2k1.5m6.9m24.6m

Accounts Receivable

312.5k3.8m4.5m

Current Assets

278.8k467.4k1.9m10.8m29.4m

Total Assets

300.7k487.8k1.9m10.8m29.4m
Quarterly
USDQ1, 2014Q2, 2014Q3, 2014Q1, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q1, 2018Q2, 2018Q3, 2018Q1, 2019Q2, 2019

Cash

323.7k420.4k180.8k1.1m455.2k1.3m2.4m1.2m12.9m9.7m5.9m11.3m11.2m24.8m23.8m23.9m

Accounts Receivable

699.1k1.6m3.0m4.1m2.0m4.3m

Current Assets

336.5k424.7k222.5k1.7m473.0k1.3m2.4m2.0m13.0m9.8m6.8m13.7m14.8m29.3m26.2m28.8m

Total Assets

359.2k447.2k244.7k1.7m493.0k1.3m2.5m2.0m13.0m9.8m6.8m13.8m14.8m29.3m26.3m28.8m
Annual
USDFY, 2014FY, 2015FY, 2016FY, 2017FY, 2018

Net Income

(11.5m)(7.0m)(7.8m)6.6m(21.2m)

Depreciation and Amortization

2.4k5.1k2.6k

Accounts Payable

159.8k114.9k(174.9k)2.1m(1.9m)

Cash From Operating Activities

(1.0m)(4.2m)(915.3k)5.6m(523.0k)
Quarterly
USDQ1, 2014Q2, 2014Q3, 2014Q1, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q1, 2018Q2, 2018Q3, 2018Q1, 2019Q2, 2019

Net Income

(1.7m)(6.8m)(7.3m)(775.3k)(11.1m)(7.1m)(6.7m)(600.6k)10.0m6.9m(5.6m)(9.3m)(10.7m)(11.7m)(1.7m)(158.0k)

Depreciation and Amortization

1.3k2.6k1.0k1.0k2.0k2.0k5.0k

Accounts Payable

(16.4k)(27.7k)(21.7k)500.9k615.6k1.3m685.0k221.0k(1.7m)(2.5m)349.0k(59.0k)

Cash From Operating Activities

(274.9k)(431.7k)(671.3k)(974.0k)(748.2k)(356.2k)732.3k(296.8k)11.6m8.4m(970.0k)2.2m678.0k(305.0k)(1.4m)(2.1m)
USDY, 2019

Financial Leverage

1.4 x
Show all financial metrics

Opiant Pharmaceuticals Online and Social Media Presence

Embed Graph

Opiant Pharmaceuticals Blogs

Opiant Pharmaceuticals Announces Presentations at Two Upcoming Investor Conferences

Opiant Pharmaceuticals Announces Presentations at Two Upcoming Investor Conferences Content Import Tue, 08/27/2019 - 16:30 Opiant Pharmaceuticals Announces Presentations at Two Upcoming Investor Conferences August 27, 2019 at 4:30 PM EDT This release is a back…

Opiant Pharmaceuticals Reports Second Quarter 2019 Financial Results and Provides Corporate Update

SANTA MONICA, Calif. , Aug. 08, 2019 (GLOBE NEWSWIRE) -- Opiant Pharmaceuticals, Inc. (“Opiant”) (NASDAQ: OPNT), a specialty pharmaceutical company developing medicines for addictions and drug overdose, today reported financial results for the second quarter and six months ended June 30, 2019 and

Opiant Pharmaceuticals Expands Partnership with Sanofi, Signs Agreement for Manufacturing OPNT004 for Treatment of Acute Cannabinoid Overdose

Opiant Pharmaceuticals Expands Partnership with Sanofi, Signs Agreement for Manufacturing OPNT004 for Treatment of Acute Cannabinoid Overdose Content Import Tue, 07/23/2019 - 08:01 Opiant Pharmaceuticals Expands Partnership with Sanofi, Signs Agreement for Manufacturing OPNT004 for Treatme…

Opiant Pharmaceuticals Announces Publication of Clinical Pharmacokinetic Data Supporting Potential of OPNT003, Nasal Nalmefene, for Treatment of Synthetic Opioid Overdose

Data published online in the Journal of Pharmacology and Experimental Therapeutics SANTA MONICA, Calif. , April 08, 2019 (GLOBE NEWSWIRE) -- Opiant Pharmaceuticals, Inc. (NASDAQ:OPNT), a specialty pharmaceutical company developing medicines for addictions and drug overdose, today announced that

Opiant Pharmaceuticals Announces Publication of Clinical Pharmacokinetic Data Supporting Potential of OPNT002, Nasal Naltrexone, for Treatment of Alcohol Use Disorder

Data published online in The Journal of Clinical Pharmacology SANTA MONICA, Calif. , April 03, 2019 (GLOBE NEWSWIRE) -- Opiant Pharmaceuticals, Inc. (NASDAQ:OPNT), a specialty pharmaceutical company developing medicines for addictions and drug overdose, today announced that clinical pharmacokinetic

Opiant Pharmaceuticals Announces Award of Second Tranche of Approximately $3.0 Million from National Institutes of Health Grant for Development of OPNT003, Nasal Nalmefene, for Treatment of Opioid Overdose

SANTA MONICA, Calif. , April 01, 2019 (GLOBE NEWSWIRE) -- Opiant Pharmaceuticals, Inc. ("Opiant") (NASDAQ: OPNT), a specialty pharmaceutical company developing medicines for addictions and drug overdose, has been awarded the second tranche of $3.0 million from the total grant of approximately $7.4
Show more

Opiant Pharmaceuticals Frequently Asked Questions

  • When was Opiant Pharmaceuticals founded?

    Opiant Pharmaceuticals was founded in 2009.

  • Who are Opiant Pharmaceuticals key executives?

    Opiant Pharmaceuticals's key executives are Roger Crystal, Kevin Pollack and Phil Skolnick.

  • How many employees does Opiant Pharmaceuticals have?

    Opiant Pharmaceuticals has 16 employees.

  • What is Opiant Pharmaceuticals revenue?

    Latest Opiant Pharmaceuticals annual revenue is $14 m.

  • What is Opiant Pharmaceuticals revenue per employee?

    Latest Opiant Pharmaceuticals revenue per employee is $873.9 k.

  • Who are Opiant Pharmaceuticals competitors?

    Competitors of Opiant Pharmaceuticals include Vitality Biopharma, E-Therapeutics and Amphastar Pharmaceuticals.

  • Where is Opiant Pharmaceuticals headquarters?

    Opiant Pharmaceuticals headquarters is located at 401 Wilshire Blvd 12th Floor, Santa Monica.

  • Where are Opiant Pharmaceuticals offices?

    Opiant Pharmaceuticals has an office in Santa Monica.

  • How many offices does Opiant Pharmaceuticals have?

    Opiant Pharmaceuticals has 1 office.